N A Jarad1, K Giles. 1. The Adult CF Centre, Bristol Royal Infirmary, Bristol, UK. Nabil.Jarad@ubht.nhs.uk
Abstract
BACKGROUND: Pulmonary exacerbations (P Exs) are important in cystic fibrosis (CF). They are very common, and are associated with poor quality of life. P Exs are regarded as an important end point in clinical trials. Risk factors associated with increase in P Exs have not been examined at a large scale. This study investigates factors associated with P Exs in a large cohort of adolescent and adult patients. PATIENTS AND METHODS: This is a cross-sectional study on data collected in the South and West Regions in England in 2002. Patients aged 16 years and over were included. Data on age, gender, FEV(1), body mass index (BMI), infection with Pseudomonas aeruginosa (Pa) and on CF-related diabetes were included in the analysis. P Ex was defined as an episode treated with IV antibiotics. Forward stepwise multiple regression analysis was performed with the number of P Exs being the independent variable. The rest of the variables were considered to be the dependent variables. RESULTS: Data from 341 patients (194 female), mean age (SD), 24.9 (8.9) years were available. In 2002, a total of 599 P Exs were reported, median 1.00 range 0-16 P Exs. Using stepwise multiple regression analysis factors associated with increased number of P Exs were: infection with Pa (t-value -5.0, P < 0.0001), FEV(1), (t-value -4.9, P < 0.0001) and diabetes mellitus, (t-value -2.1, P = 0.04). Age, gender and BMI did not influence the annual number of exacerbations. CONCLUSIONS: In this study, risk factors for P Exs were found to be as follows: growth of Pa in the sputum, reduced FEV1 and CF-related diabetes mellitus.
BACKGROUND: Pulmonary exacerbations (P Exs) are important in cystic fibrosis (CF). They are very common, and are associated with poor quality of life. P Exs are regarded as an important end point in clinical trials. Risk factors associated with increase in P Exs have not been examined at a large scale. This study investigates factors associated with P Exs in a large cohort of adolescent and adult patients. PATIENTS AND METHODS: This is a cross-sectional study on data collected in the South and West Regions in England in 2002. Patients aged 16 years and over were included. Data on age, gender, FEV(1), body mass index (BMI), infection with Pseudomonas aeruginosa (Pa) and on CF-related diabetes were included in the analysis. P Ex was defined as an episode treated with IV antibiotics. Forward stepwise multiple regression analysis was performed with the number of P Exs being the independent variable. The rest of the variables were considered to be the dependent variables. RESULTS: Data from 341 patients (194 female), mean age (SD), 24.9 (8.9) years were available. In 2002, a total of 599 P Exs were reported, median 1.00 range 0-16 P Exs. Using stepwise multiple regression analysis factors associated with increased number of P Exs were: infection with Pa (t-value -5.0, P < 0.0001), FEV(1), (t-value -4.9, P < 0.0001) and diabetes mellitus, (t-value -2.1, P = 0.04). Age, gender and BMI did not influence the annual number of exacerbations. CONCLUSIONS: In this study, risk factors for P Exs were found to be as follows: growth of Pa in the sputum, reduced FEV1 and CF-related diabetes mellitus.
Authors: I M Sequeiros; K Hester; M Callaway; A Williams; Z Garland; T Powell; F S Wong; N A Jarad Journal: Br J Radiol Date: 2010-11 Impact factor: 3.039
Authors: Daniela Savi; Nicholas Simmonds; Marcello Di Paolo; Serena Quattrucci; Paolo Palange; Winston Banya; Nicholas S Hopkinson; Diana Bilton Journal: BMC Pulm Med Date: 2015-12-01 Impact factor: 3.317
Authors: James P Garnett; Michael A Gray; Robert Tarran; Malcolm Brodlie; Christopher Ward; Emma H Baker; Deborah L Baines Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240
Authors: Julia C Espel; Hannah L Palac; Joanne F Cullina; Alexandria P Clarke; Susanna A McColley; Michelle H Prickett; Manu Jain Journal: BMC Pulm Med Date: 2017-11-29 Impact factor: 3.317
Authors: Annika Åstrand; Cecilia Wingren; Audra Benjamin; John S Tregoning; James P Garnett; Helen Groves; Simren Gill; Maria Orogo-Wenn; Anders J Lundqvist; Dafydd Walters; David M Smith; John D Taylor; Emma H Baker; Deborah L Baines Journal: Br J Pharmacol Date: 2017-03-09 Impact factor: 8.739